Gastrointestinal Diagnostics

Global Gastrointestinal Diagnostics Market to Reach US$5.8 Billion by 2030

The global market for Gastrointestinal Diagnostics estimated at US$4.9 Billion in the year 2024, is expected to reach US$5.8 Billion by 2030, growing at a CAGR of 2.8% over the analysis period 2024-2030. Endoscopy Test, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$1.6 Billion by the end of the analysis period. Growth in the Blood Test segment is estimated at 1.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 5.1% CAGR

The Gastrointestinal Diagnostics market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 5.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.1% and 2.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.

Global Gastrointestinal Diagnostics Market – Key Trends & Drivers Summarized

How Are Advancements in Gastrointestinal Diagnostics Improving Disease Detection?

Gastrointestinal (GI) diagnostics have witnessed significant advancements in recent years, driven by the increasing prevalence of GI disorders and the need for early and accurate disease detection. Conditions such as inflammatory bowel disease (IBD), colorectal cancer, peptic ulcers, gastroesophageal reflux disease (GERD), and celiac disease require timely and precise diagnostic tools to ensure effective treatment. Traditional diagnostic methods such as endoscopy, colonoscopy, and stool analysis remain the cornerstone of GI disease detection, but emerging technologies are enhancing diagnostic accuracy, reducing procedure times, and improving patient outcomes.

Recent innovations in GI diagnostics include capsule endoscopy, molecular biomarker testing, and artificial intelligence (AI)-assisted imaging. Capsule endoscopy enables non-invasive visualization of the entire digestive tract, particularly the small intestine, which is difficult to assess using conventional endoscopy. AI-powered diagnostic tools are improving the detection of precancerous lesions, polyps, and other abnormalities in endoscopic images, reducing the risk of human error. Furthermore, advancements in liquid biopsy and microbiome analysis are enabling personalized diagnostics, helping physicians tailor treatment strategies based on individual patient profiles. As these technologies continue to evolve, gastrointestinal diagnostics are becoming more accessible, efficient, and precise.

Which GI Diagnostic Technologies Are Driving Market Growth?

The demand for advanced gastrointestinal diagnostics is growing across multiple healthcare settings, including hospitals, diagnostic laboratories, and ambulatory care centers. Endoscopy remains the gold standard for diagnosing GI disorders, but new imaging modalities such as confocal laser endomicroscopy (CLE) and fluorescence endoscopy are enhancing the ability to detect mucosal abnormalities in real time. High-resolution manometry (HRM) is also being increasingly adopted for diagnosing esophageal motility disorders, providing valuable insights into swallowing dysfunction and reflux-related conditions.

Molecular diagnostics and genetic testing are also playing a growing role in the early detection of gastrointestinal cancers and hereditary GI diseases. Next-generation sequencing (NGS) enables precise identification of genetic mutations linked to conditions such as Lynch syndrome and hereditary pancreatitis, allowing for proactive disease management. Additionally, the rise of point-of-care testing (POCT) for GI infections, such as Helicobacter pylori and Clostridium difficile, has improved rapid diagnosis and treatment initiation. With the increasing focus on non-invasive and minimally invasive diagnostics, the GI diagnostics market is poised for substantial expansion in the coming years.

What Are the Latest Technological Advancements in Gastrointestinal Diagnostics?

Technological innovations are transforming gastrointestinal diagnostics by enhancing detection capabilities, reducing procedure times, and improving patient comfort. One of the most significant breakthroughs is the integration of AI into endoscopic and imaging procedures. AI algorithms can analyze endoscopic videos in real time, identifying abnormalities such as polyps, tumors, and inflammation with high accuracy. This technology is helping endoscopists detect early-stage colorectal cancer and precancerous lesions more effectively, reducing the incidence of missed diagnoses.

Additionally, liquid biopsy is emerging as a revolutionary tool for non-invasive GI cancer detection. By analyzing circulating tumor DNA (ctDNA) and other biomarkers in the blood, liquid biopsy offers a less invasive alternative to traditional biopsy procedures. Another key advancement is the development of smart capsule endoscopy, which enables wireless monitoring of gut motility and pH levels, providing valuable insights into digestive health without requiring sedation or hospital visits. These innovations are making GI diagnostics more efficient, patient-friendly, and capable of detecting diseases at earlier stages.

What Factors Are Fueling the Growth of the Gastrointestinal Diagnostics Market?

The growth in the gastrointestinal diagnostics market is driven by several factors, including the rising incidence of GI disorders, increasing adoption of advanced imaging technologies, and the shift toward non-invasive diagnostic methods. The global burden of colorectal cancer and inflammatory bowel diseases has led to greater demand for early screening and precision diagnostics. Government initiatives promoting colon cancer screening programs and improved healthcare infrastructure have also contributed to market expansion.

Technological advancements, such as AI-assisted endoscopy, liquid biopsy, and microbiome-based diagnostics, are further accelerating market growth. The increasing preference for home-based and point-of-care testing solutions has expanded patient access to GI diagnostics, particularly in underserved regions. Additionally, the expansion of telemedicine and digital health platforms is enabling remote GI consultations and diagnostic assessments. As healthcare providers continue to emphasize early detection and personalized medicine, the gastrointestinal diagnostics market is expected to experience sustained growth, driven by innovation and rising healthcare awareness.

SCOPE OF STUDY:

The report analyzes the Gastrointestinal Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Test (Endoscopy Test, Blood Test, H. Pylori Test, Calprotectin Test, Immunoglobulin Test, Other Gastrointestinal Diagnostics Tests); Technology (ELISA Technology, PCR Technology, Microbiology Technology, Other Technologies); Test Location (Central Laboratories Test Location, Point-of-Care Test Location); Application (Infection, Inflammatory Bowel Disease Application, Gastroesophageal Reflux Disease Application, Cancer Application, Other Applications)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Abbott Laboratories
• Beckman Coulter, Inc.
• bioMérieux
• Boston Scientific Corporation
• Cardinal Health
• Danaher Corporation
• DiaSorin S.p.A
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd.
• Fujifilm Holdings Corporation
• Genova Diagnostics
• Guardant Health, Inc.
• Hologic, Inc.
• Medtronic plc
• Meridian Bioscience
• Olympus Corporation
• QIAGEN
• Quest Diagnostics
• Siemens Healthineers AG
• Stryker Corporation

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.